The drug aspirin, sometimes called blood thinner, may be used to treat COVID-19. The largest volume of research in this area will be launched in the UK.
As we already know, people infected with the new type of coronavirus are at increased risk of complications caused by clots formed as a result of blood clotting. The exact reason for this is not entirely certain, but it is clear that hyper-reactive platelets contribute to this. The latter are responsible for stopping the blood clotting and thus the bleeding.
Aspirin, on the other hand, is an antithrombotic drug that can reduce the risk of developing blood clots, according to a statement posted on the study’s website. As it turns out, at least 2,000 patients involved in the study will receive 150 mg of aspirin randomly in addition to their usual prescription. These data scientists will later compare with the data of the other 2,000 volunteers who were not prescribed this medication during the course of treatment.
“There is a solid basis for believing that it [aspirin] has a beneficial effect, is safe, cheap and affordable,” said Peter Horby, the project’s lead co-researcher.
Remedisivir is currently registered as the official treatment for COVID-19 in the United States. It should be noted that in a study conducted by the World Health Organization, this drug did not show very good results, and this was followed by a corresponding noise in scientific circles. This antiviral drug is produced by the company Gilead. In contrast, aspirin is a generic drug, which makes its production even cheaper.
The team of scientists behind the new research already has extensive experience. The UK-initiated COVID-19 Therapy Randomized Evaluation Therapy Project is also called the RECOVERY study, and was one of the first researchers to prove the effectiveness of dexamethasone, saving thousands of lives.
The same scientific group found that hydroxychloroquine (same as plaquenil) was not effective in treating patients. Currently, in addition to a new study of aspirin, a group of British scientists is studying the effects of the antibiotic cocktail created by the antibiotic azithromycin and the pharmaceutical company Regeneron on COVID-19.